Alvotech and Teva announce Strategic Partnership

Alvotech and Teva Pharmaceutical have announced a strategic partnership where Teva will commercialize Alvotech's biologics products in the U.S. The initial pipeline contains five biosimilar product candidates from Alvotech.

Mark Levick, CEO of Alvotech says in a statement: “Teva is an ideal commercial partner for Alvotech and combines their leading commercial footprint and track record in the U.S. market with Alvotech’s scientific experience and state-of-the-art biologics manufacturing."

Alvotech is a fully integrated biopharmaceutical company focused on the development and manufacturing of biosimilar medicine. In the headquarters in Reykjavik, Iceland, Alvotech has cutting-edge in-house R&D capabilities, from cell line process and product development, through scale-up and manufacturing. Alvotech has attracted an international team of biopharmaceutical specialists. 

Teva is a global leader in generic and specialty medicines with a portfolio of over 3,500 products in almost all therapeutic areas. 

For further information see the announcements from Alvotech and Teva.

Get in touch

For further information on the benefits of establishing a business in Iceland please feel free to contact us.


Iceland focuses on a favorable business environment, including low corporate tax, availability of land and green energy at competitive prices and efficiency within European legislative framework. Generous support for R&D.

Why Iceland

Along with having one of the lowest corporate tax rate in Europe, Iceland has a highly educated workforce which is ranked among the highest in the world, offers competitively priced renewable energy with an advanced infrastructure making Iceland an ideal location for investors